{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T13:27:14Z","timestamp":1679232434575},"reference-count":72,"publisher":"AACN Publishing","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6,1]]},"abstract":"<jats:p>Acid-suppressive therapy for prophylaxis of stress ulcer bleeding is commonly prescribed for hospitalized patients. Although its use in select, at-risk patients may reduce clinically significant gastrointestinal bleeding, the alteration in gastric pH and composition may place these patients at a higher risk of infection. Although any pharmacologic alteration of the gastric pH and composition is associated with an increased risk of infection, the risk appears to be highest with proton pump inhibitors, perhaps owing to the potency of this class of drugs in increasing the gastric pH. With the increased risk of infection, universal provision of pharmacologic acid suppression to all hospitalized patients, even all critically ill patients, is inappropriate and should be confined to patients meeting specific criteria. Nurses providing care in critical care areas may be instrumental in screening for appropriate use of acid-suppressive therapy and ensuring the drugs are discontinued upon transfer out of intensive care or when risk factors are no longer present.<\/jats:p>","DOI":"10.4037\/ccn2017720","type":"journal-article","created":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T04:15:14Z","timestamp":1496290514000},"page":"18-29","source":"Crossref","is-referenced-by-count":2,"title":["Prophylactic Acid-Suppressive Therapy in Hospitalized Adults: Indications, Benefits, and Infectious Complications"],"prefix":"10.4037","volume":"37","author":[{"given":"Andrew C.","family":"Faust","sequence":"first","affiliation":[{"name":"Andrew C. Faust is a critical care clinical pharmacist primarily working in the medical intensive care unit, Department of Pharmacy, Texas Health Presbyterian Hospital Dallas, Dallas, Texas."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly L.","family":"Echevarria","sequence":"additional","affiliation":[{"name":"Kelly L. Echevarria is an infectious diseases and critical care clinical pharmacist, Department of Pharmacy, South Texas Veterans Health Care System, San Antonio, Texas."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca L.","family":"Attridge","sequence":"additional","affiliation":[{"name":"Rebecca L. Attridge is an associate professor, Department of Pharmacy Practice, University of the Incarnate Word Feik School of Pharmacy, and an adjunct assistant professor, Division of Pulmonary Diseases and Critical Care Medicine, Department of Medicine, UT Health San Antonio, San Antonio, Texas."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyndsay","family":"Sheperd","sequence":"additional","affiliation":[{"name":"Lyndsay Sheperd is a critical care clinical pharmacist primarily working in the surgical-trauma intensive care unit, Department of Pharmacy, Texas Health Presbyterian Hospital Dallas, Dallas, Texas."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos I.","family":"Restrepo","sequence":"additional","affiliation":[{"name":"Marcos I. Restrepo is an associate professor in pulmonary and critical care medicine, Department of Medicine, Division of Pulmonary Diseases and Critical Care Medicine, University of Texas Health Science Center at San Antonio, and Veterans Evidence-Based Research Dissemination Implementation Center, South Texas Veterans Health Care System, San Antonio, Texas."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2471","reference":[{"issue":"4","key":"2019112519054851800_b1-0370018","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0002-9610(69)90011-7","article-title":"Respiratory failure, hypotension, sepsis, and jaundice: a clinical syndrome associated with lethal hemorrhage from acute stress ulceration of the stomach","volume":"117","author":"Skillman","year":"1969","journal-title":"Am J Surg"},{"issue":"4","key":"2019112519054851800_b2-0370018","first-page":"347","article-title":"ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998","volume":"56","author":"ASHP therapeutic guidelines on stress ulcer prophylaxis","year":"1999","journal-title":"Am J Health Syst Pharm"},{"issue":"2","key":"2019112519054851800_b3-0370018","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00134-012-2769-8","article-title":"Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012","volume":"39","author":"Dellinger","year":"2013","journal-title":"Intensive Care Med"},{"key":"2019112519054851800_b4-0370018","article-title":"Prevention of clinically significant gastrointestinal bleeding in intensive care unit patients","volume-title":"Making Health Care Safer: A Critical Analysis of Patient Safety Practices","author":"Dressler","year":"2001"},{"issue":"10","key":"2019112519054851800_b5-0370018","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1111\/j.1572-0241.2006.00839.x","article-title":"Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients","volume":"101","author":"Heidelbaugh","year":"2006","journal-title":"Am J Gastroenterol"},{"issue":"13","key":"2019112519054851800_b6-0370018","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.2146\/ajhp060393","article-title":"Stress ulcer prophylaxis in hospitalized patients not in intensive care units","volume":"64","author":"Grube","year":"2007","journal-title":"Am J Health-Syst Pharm"},{"issue":"12","key":"2019112519054851800_b7-0370018","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1097\/00003246-199422120-00010","article-title":"Prospective endoscopic study of stress erosions and ulcers in critically ill adult patients treated with either sucralfate or placebo","volume":"22","author":"Eddleston","year":"1994","journal-title":"Crit Care Med"},{"issue":"2","key":"2019112519054851800_b8-0370018","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.gtc.2009.03.002","article-title":"Stress-induced ulcer bleeding in critically ill patients","volume":"38","author":"Ali","year":"2009","journal-title":"Gastroenterol Clin North Am"},{"issue":"7","key":"2019112519054851800_b9-0370018","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/aas.12099","article-title":"Stress ulcer prophylaxis in the intensive care unit: is it indicated? A topical systematic review","volume":"57","author":"Krag","year":"2013","journal-title":"Acta Anaesthesiol Scand"},{"issue":"6","key":"2019112519054851800_b10-0370018","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1056\/NEJM199402103300601","article-title":"Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group","volume":"330","author":"Cook","year":"1994","journal-title":"N Engl J Med"},{"issue":"1","key":"2019112519054851800_b11-0370018","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s12028-011-9580-1","article-title":"Gastrointestinal prophylaxis in neurocritical care","volume":"16","author":"Schirmer","year":"2012","journal-title":"Neurocrit Care"},{"issue":"2","key":"2019112519054851800_b12-0370018","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1378\/chest.08-1634","article-title":"Nosocomial pneumonia risk and stress ulcer prophylaxis: a comparison of pantoprazole vs ranitidine in cardiothoracic surgery patients","volume":"136","author":"Miano","year":"2009","journal-title":"Chest"},{"issue":"11","key":"2019112519054851800_b13-0370018","first-page":"3118","article-title":"Overuse of acid-suppressive therapy in hospitalized patients","volume":"95","author":"Nardino","year":"2000","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"2019112519054851800_b14-0370018","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/jhm.10","article-title":"Hospital-acquired gastrointestinal bleeding outside the critical care unit: risk factors, role of acid suppression, and endoscopy findings","volume":"1","author":"Qadeer","year":"2006","journal-title":"J Hosp Med"},{"issue":"11","key":"2019112519054851800_b15-0370018","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archinternmed.2011.14","article-title":"Acid-suppressive medication use and the risk for nosocomial gastrointestinal tract bleeding","volume":"171","author":"Herzig","year":"2011","journal-title":"Arch Intern Med"},{"issue":"8","key":"2019112519054851800_b16-0370018","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3109\/00365529109037018","article-title":"Prophylaxis of gastrointestinal tract bleeding with magaldrate in patients admitted to a general hospital ward","volume":"26","author":"Estruch","year":"1991","journal-title":"Scand J Gastroenterol"},{"issue":"3","key":"2019112519054851800_b17-0370018","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3109\/00365529309096080","article-title":"Prophylaxis of gastrointestinal tract bleeding in patients admitted to a general hospital ward. Comparative study of sucralfate and cimetidine","volume":"28","author":"Grau","year":"1993","journal-title":"Scand J Gastroenterol"},{"issue":"5","key":"2019112519054851800_b18-0370018","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s11606-012-2296-x","article-title":"Risk factors for nosocomial gastrointestinal bleeding and use of acid-suppressive medication in non-critically ill patients","volume":"28","author":"Herzig","year":"2013","journal-title":"J Gen Intern Med"},{"issue":"9","key":"2019112519054851800_b19-0370018","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1177\/1060028015592014","article-title":"Acid suppressive therapy for stress ulcer prophylaxis in noncritically ill patients","volume":"49","author":"Hong","year":"2015","journal-title":"Ann Pharmacother"},{"issue":"8","key":"2019112519054851800_b20-0370018","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.amjmed.2015.02.014","article-title":"Impact of a clinical pharmacist stress ulcer prophylaxis management program on inappropriate use in hospitalized patients","volume":"128","author":"Buckley","year":"2015","journal-title":"Am J Med"},{"key":"2019112519054851800_b21-0370018","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1310\/hpj4410-888","article-title":"Evaluation of continuation of stress ulcer prophylaxis at hospital discharge","volume":"44","author":"Judd","year":"2009","journal-title":"Hosp Pharm"},{"issue":"19","key":"2019112519054851800_b22-0370018","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1056\/NEJM197805112981901","article-title":"Antacid titration in the prevention of acute gastrointestinal bleeding: a controlled, randomized trial in 100 critically ill patients","volume":"298","author":"Hastings","year":"1978","journal-title":"N Engl J Med"},{"issue":"12","key":"2019112519054851800_b23-0370018","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1056\/NEJM199803193381203","article-title":"A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group","volume":"338","author":"Cook","year":"1998","journal-title":"N Engl J Med"},{"issue":"3","key":"2019112519054851800_b24-0370018","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/CCM.0b013e3182758734","article-title":"Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis","volume":"41","author":"Alhazzani","year":"2013","journal-title":"Crit Care Med"},{"issue":"4","key":"2019112519054851800_b25-0370018","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1097\/CCM.0b013e3181d69ccf","article-title":"The efficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients: a meta-analysis","volume":"38","author":"Lin","year":"2010","journal-title":"Crit Care Med"},{"issue":"4","key":"2019112519054851800_b26-0370018","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/jamainternmed.2013.14673","article-title":"Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit","volume":"174","author":"MacLaren","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"11","key":"2019112519054851800_b27-0370018","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1097\/CCM.0b013e3181f17adf","article-title":"Stress ulcer prophylaxis in the new millennium: a systematic review and meta-analysis","volume":"38","author":"Marik","year":"2010","journal-title":"Crit Care Med"},{"issue":"1","key":"2019112519054851800_b28-0370018","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00134-013-3125-3","article-title":"Stress ulcer prophylaxis versus placebo or no prophylaxis in critically ill patients: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis","volume":"40","author":"Krag","year":"2014","journal-title":"Intensive Care Med"},{"issue":"2","key":"2019112519054851800_b29-0370018","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1742-7843.2005.pto960202.x","article-title":"Gastric juice: a barrier against infectious diseases","volume":"96","author":"Martinsen","year":"2005","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"2019112519054851800_b30-0370018","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/gut.28.1.96","article-title":"Relationship between gastric secretion and infection","volume":"28","author":"Howden","year":"1987","journal-title":"Gut"},{"issue":"3489","key":"2019112519054851800_b31-0370018","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/bmj.2.3849.665","article-title":"The clinical importance of achlorhydria","volume":"2","author":"Hurst","year":"1934","journal-title":"Br Med J"},{"issue":"2","key":"2019112519054851800_b32-0370018","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1128\/IAI.01138-07","article-title":"Influence of gastric acid on susceptibility to infection with ingested bacterial pathogens","volume":"76","author":"Tennant","year":"2008","journal-title":"Infect Immun"},{"issue":"4","key":"2019112519054851800_b33-0370018","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","article-title":"Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia","volume":"171","author":"American Thoracic Society; Infectious Diseases Society of America","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"2019112519054851800_b34-0370018","first-page":"910","article-title":"The gastrointestinal tract and ventilator-associated pneumonia","volume":"50","author":"Kallet","year":"2005","journal-title":"Respir Care"},{"issue":"3","key":"2019112519054851800_b35-0370018","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/clinids\/24.3.309","article-title":"Role of colonization of the upper intestinal tract in the pathogenesis of ventilator-associated pneumonia","volume":"24","author":"Bonten","year":"1997","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2019112519054851800_b36-0370018","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4292\/wjgpt.v2.i3.17","article-title":"Proton pump inhibitor-associated pneumonia: not a breath of fresh air after all?","volume":"2","author":"Fohl","year":"2011","journal-title":"World J Gastrointest Pharmacol Ther"},{"issue":"8","key":"2019112519054851800_b37-0370018","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1046\/j.1365-2036.2003.01744.x","article-title":"Gastric acid-suppressive therapy and community-acquired respiratory infections","volume":"18","author":"Laheij","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"16","key":"2019112519054851800_b38-0370018","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1001\/jama.292.16.1955","article-title":"Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs","volume":"292","author":"Laheij","year":"2004","journal-title":"JAMA"},{"issue":"9","key":"2019112519054851800_b39-0370018","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1001\/archinte.167.9.950","article-title":"Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study","volume":"167","author":"Gulmez","year":"2007","journal-title":"Arch Intern Med"},{"issue":"4","key":"2019112519054851800_b40-0370018","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/pds.1715","article-title":"Risk of community-acquired pneumonia and the use of statins, ACE inhibitors and gastric acid suppressants: a population-based case-control study","volume":"18","author":"Myles","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"2019112519054851800_b41-0370018","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/EDE.0b013e3181b5f27d","article-title":"Acid-suppressive drugs and community-acquired pneumonia","volume":"20","author":"Rodr\u00edguez","year":"2009","journal-title":"Epidemiology"},{"issue":"5","key":"2019112519054851800_b42-0370018","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1183\/09031936.00020811","article-title":"Microbial evaluation of proton-pump inhibitors and the risk of pneumonia","volume":"38","author":"Meijvis","year":"2011","journal-title":"Eur Respir J"},{"issue":"1","key":"2019112519054851800_b43-0370018","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/cid\/cir767","article-title":"Risk of community-acquired pneumonia in veteran patients to whom proton pump inhibitors were dispensed","volume":"54","author":"Hermos","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2019112519054851800_b44-0370018","doi-asserted-by":"crossref","first-page":"391","DOI":"10.7326\/0003-4819-149-6-200809160-00005","article-title":"Proton-pump inhibitor use and the risk for community-acquired pneumonia","volume":"149","author":"Sarkar","year":"2008","journal-title":"Ann Intern Med"},{"issue":"11","key":"2019112519054851800_b45-0370018","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/j.1365-2036.2010.04284.x","article-title":"Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia","volume":"31","author":"Johnstone","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"2019112519054851800_b46-0370018","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1503\/cmaj.092129","article-title":"Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis","volume":"183","author":"Eom","year":"2011","journal-title":"CMAJ"},{"issue":"8","key":"2019112519054851800_b47-0370018","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/pds.1978","article-title":"Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population-based case-control study","volume":"19","author":"Dublin","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"2019112519054851800_b48-0370018","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1136\/gutjnl-2013-304738","article-title":"Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis","volume":"63","author":"Filion","year":"2014","journal-title":"Gut"},{"issue":"8","key":"2019112519054851800_b49-0370018","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1164\/rccm.201301-0079OC","article-title":"Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia","volume":"188","author":"Shindo","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"2019112519054851800_b50-0370018","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/ajg.2011.474","article-title":"Proton pump inhibitors vs. histamine 2 receptor antagonists for stress-related mucosal bleeding prophylaxis in critically ill patients: a meta-analysis","volume":"107","author":"Barkun","year":"2012","journal-title":"Am J Gastroenterol"},{"issue":"20","key":"2019112519054851800_b51-0370018","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1001\/jama.2009.722","article-title":"Acid-suppressive medication use and the risk for hospital-acquired pneumonia","volume":"301","author":"Herzig","year":"2009","journal-title":"JAMA"},{"issue":"14","key":"2019112519054851800_b52-0370018","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1053\/jcrc.2002.36761","article-title":"Occurrence of ventilator-associated pneumonia in mechanically ventilated pediatric intensive care patients during stress ulcer prophylaxis with sucralfate, ranitidine, and omeprazole","volume":"17","author":"Yildizdas","year":"2002","journal-title":"J Crit Care"},{"issue":"5","key":"2019112519054851800_b53-0370018","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.cursur.2004.03.014","article-title":"Do proton pump inhibitors increase the incidence of nosocomial pneumonia and related infectious complications when compared with histamine-2 receptor antagonists in critically ill trauma patients?","volume":"61","author":"Mallow","year":"2004","journal-title":"Curr Surg"},{"issue":"4","key":"2019112519054851800_b54-0370018","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jcrc.2007.11.003","article-title":"Do proton-pump inhibitors increase the risk for nosocomial pneumonia in a medical intensive care unit?","volume":"23","author":"Beaulieu","year":"2008","journal-title":"J Crit Care"},{"key":"2019112519054851800_b55-0370018","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/978-3-7091-0693-8_75","article-title":"Proton pump inhibitor prophylaxis increases the risk of nosocomial pneumonia in patients with an intracerebral hemorrhagic stroke","volume":"111","author":"Ran","year":"2011","journal-title":"Acta Neurochir Suppl"},{"issue":"5","key":"2019112519054851800_b56-0370018","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1086\/651669","article-title":"Economic burden of ventilator-associated pneumonia based on total resource utilization","volume":"31","author":"Restrepo","year":"2010","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"3","key":"2019112519054851800_b57-0370018","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1086\/664049","article-title":"Economic impact of ventilator-associated pneumonia in a large matched cohort","volume":"33","author":"Kollef","year":"2012","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"3","key":"2019112519054851800_b58-0370018","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1017\/S0950268897008224","article-title":"Diabetes mellitus, anti-secretory drugs and other risk factors for campylobacter gastro-enteritis in adults: a case-control study","volume":"119","author":"Neal","year":"1997","journal-title":"Epidemiol Infect"},{"issue":"9","key":"2019112519054851800_b59-0370018","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1111\/j.1572-0241.2007.01275.x","article-title":"Systematic review of the risk of enteric infection in patients taking acid suppression","volume":"102","author":"Leonard","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"2019112519054851800_b60-0370018","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/cid\/ciu628","article-title":"Association between recent use of proton pump inhibitors and nontyphoid salmonellosis: a nested case-control study","volume":"59","author":"Wu","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2019112519054851800_b61-0370018","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/j.1742-1241.2011.02650.x","article-title":"Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients\u2014a systematic review and meta-analysis","volume":"65","author":"Trikudanathan","year":"2011","journal-title":"Int J Clin Pract"},{"issue":"2","key":"2019112519054851800_b62-0370018","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/jgh.12065","article-title":"Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis","volume":"28","author":"Deshpande","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"issue":"11","key":"2019112519054851800_b63-0370018","doi-asserted-by":"crossref","first-page":"e110503","DOI":"10.1371\/journal.pone.0110503","article-title":"Proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites","volume":"9","author":"Mandorfer","year":"2014","journal-title":"PLoS One"},{"issue":"22","key":"2019112519054851800_b64-0370018","doi-asserted-by":"crossref","first-page":"e944","DOI":"10.1097\/MD.0000000000000944","article-title":"Risk of spontaneous bacterial peritonitis associated with gastric acid suppression","volume":"94","author":"Chang","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"2019112519054851800_b65-0370018","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.cgh.2011.09.030","article-title":"Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis","volume":"10","author":"Deshpande","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"2019112519054851800_b66-0370018","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/ajg.2012.179","article-title":"Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis","volume":"107","author":"Janarthanan","year":"2012","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"2019112519054851800_b67-0370018","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/ajg.2012.108","article-title":"Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis","volume":"107","author":"Kwok","year":"2012","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"2019112519054851800_b68-0370018","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1001\/jamainternmed.2015.42","article-title":"Continuous proton pump inhibitor therapy and the associated risk of recurrent Clostridium difficile infection","volume":"175","author":"MacDonald","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"9","key":"2019112519054851800_b69-0370018","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/archinternmed.2010.73","article-title":"Proton pump inhibitors and risk for recurrent Clostridium difficile infection","volume":"170","author":"Linsky","year":"2010","journal-title":"Arch Intern Med"},{"issue":"2","key":"2019112519054851800_b70-0370018","doi-asserted-by":"crossref","first-page":"e000028","DOI":"10.1136\/bmjgast-2014-000028","article-title":"Effects of proton pump inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients with Clostridium difficile-associated diarrhea","volume":"2","author":"Weiss","year":"2015","journal-title":"BMJ Open Gastroenterol"},{"issue":"S2","key":"2019112519054851800_b71-0370018","doi-asserted-by":"crossref","first-page":"S148","DOI":"10.1093\/cid\/civ142","article-title":"Pathway to prevention of nosocomial Clostridium difficile infection","volume":"60","author":"Goldstein","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2019112519054851800_b72-0370018","unstructured":"US Food and Drug Administration. FDA drug safety communication: Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors. 2014. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm290510.htm. Accessed February 28, 2017."}],"container-title":["Critical Care Nurse"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/aacnjournals.org\/ccnonline\/article-pdf\/37\/3\/18\/120558\/18.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/aacnjournals.org\/ccnonline\/article-pdf\/37\/3\/18\/120558\/18.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T19:09:37Z","timestamp":1574708977000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacnjournals.org\/ccnonline\/article\/37\/3\/18\/3564\/Prophylactic-AcidSuppressive-Therapy-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,1]]},"references-count":72,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6,1]]}},"URL":"https:\/\/doi.org\/10.4037\/ccn2017720","relation":{},"ISSN":["0279-5442","1940-8250"],"issn-type":[{"value":"0279-5442","type":"print"},{"value":"1940-8250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,1]]}}}